by
Lorna Cvetkovich, M.D., FACOG
Rapkin, Andrea J. et.al., Progesterone Metabolite Allopregnanolone in Women with PMS. Fertility and Sterility 90 (Nov. 97): 709-714.
Since the etiology of PMS remains a mystery despite much research, a metabolite of Progesterone (P4), allopregnanolone was evaluated for its possible role in this widespread and often difficult to threat syndrome. 35 women with prospectively documented PMS were compared with 36 controls. Serum P4 and allopregnanolone levels were measured on day 5 and 12 after ovulation as determined by LH detection kits. They indeed found that allopregnanolone levels were significantly lower on day 26 in the PMS group than in controls. Allopregnanolone is known to be anxiolytic and thus its lack could lead to irritability, depression, and anxiety - some of the common symptoms of PMS. If this finding is born out by further study, it could explain why Xanax (a tranquilizer) and Prozac (a serotonin reuptake inhibitor) are effective in PMS as well as why total P4 levels have not been found to be different in women with and without PMS.
Rosenberg, L., et.al., Modern Oral Contraceptives and Cardiovascular Disease. American Journal Obstetrics and Gynecology 177 (Sept. 1997): 707-714.
Epidemiological studies established that 1st generation OCs (>50 mcg or more of Estrogen) increased the risk of thromboembolism, stroke, and heart attacks in young women. Subsequent formulations with < 50 mcg E2 and new progestins (levonorgestrel - second generation, and gestodene and norgestimate - third generation) have been developed to reduce those risks. Evidence on the cardiovascular safety of second and third generation OCs has emerged only recently. A "pill scare" was noted after a recommendation by the British Committee on Safety of Medicines that OCs containing desogesterel or gestodene be used by women who could not tolerate other formulations. The studies indicating a double rate of thromboembolism with those compounds have just now been published. Since third generation OCs have captured 15% of the market, and the remaining 85% are second generation, the data are important. The article reviewed evidence on the safety of low estrogen second and third generation OCs. The studies reviewed included the WHO Collaborative Study, the Transnational Study, the General Practice Research Database, and the Meditel Studies. Overall the combined data suggested that use of second and third generation OCs is associated with a smaller increase in the incidence of thromboembolism than earlier formulations. With regard to myocardial infarction, there was a smaller increase in risk with second and third generation OCs as well. And finally, the recent studies of stroke indicate little or no increase in risk with newer formulations among women with no risk factors. They concluded that modern combined OCs are safer than earlier formulations with respect to cardiovascular disease. Probably the results can be interpreted also to indicate what has always been thought...that the major side effects and complications due to OCs are Estrogen related and the progestational agents are not implicated in the cardiovascular (particularly thromboembolic) risk. One still wonders given the effectiveness (and lack of risk)of NFP methods why doctors would prescribe OCs with such risks at all.
Fertility/Infertility
Abstracts
Fauchin, Renato, et.al., Transvaginal Administration of Progesterone. Obstetrics and Gynecology 90 (September. 1997) 396-401.
Achieving an adequate progestational effect is important in several areas of Ob/Gyn...support of an early pregnancy in women with luteal phase defect and secretory transformation of the endometrium in women who are on estrogen replacement to name a few. The current study was done to analyze the endometrial effect of varying Progesterone (P4) levels using a new form of P4 (Crinone; P4 in a sustained release, vaginal gel) while keeping estrogen levels within the menstrual cycle range. All subjects had premature ovarian failure or ovarian dysgenesis and thus no active ovarian tissue. All received transdermal estrogen in a scheduled dosage. In addition they received either 45 (N=14), 90 (N=13), or 180 mg (N=13) of progesterone gel (Crinone) on days 15 to 27 of their cycles. Weekly FSH, LH, Estrone, Estradiol, and Progesterone levels were obtained. An endometrial biopsy was preformed on either day 20 or 24. Endometrial dating was done according to Noyes et.al. In all groups, secretory transformation of the endometrium in the glands (by day 20) and stroma (day 24) was seen as well as a normal distribution of estrogen and progesterone receptors. This effect was noted despite low plasma levels of progesterone and varying but normal menstrual levels of E2. These results suggest that during the luteal phase, progesterone alone controls secretory transformation as long as adequate estrogen priming has been achieved in the follicular phase. It also suggests a direct transit into the uterus or "first uterine pass" effect. This form of natural Progesterone may eventually have wide usage giving its superior effect on the endometrium and reduced systemic levels. (LC)
Porcu, et.al., Birth of a healthy female after intracytoplasmic sperm injection of cryopreserved human oocytes. Fertility and Sterility 68 (October, 1997): 724-726.
This is the report that made headlines for the use of not one but two "assisted reproductive technologies" in the "production" of a live birth. In the past embryos were frozen for use in subsequent cycles because they survived the freeze/thaw process better than oocytes, but of course this brought along with it many attendant ethical dilemmas which the investigators in this report thought would not be present if only the oocytes were frozen. In this case, a woman scheduled for IVF underwent ovarian hyperstimulation but when the time came for the husband to produce a semen sample, he was unable. Because 12 oocytes had been harvested, and now could not be utilized, they were frozen using a slow step wise process that would allow them to remain viable after rapid thawing. Several months later, the oocytes were thawed, and inseminated using intracytoplasmic sperm injection (ICSI), which had been shown to produce a higher rate of fertilization in such cycles. After thawing, 4 of the 12 oocytes survived. After ICSI, two fertilized, but only one cleaved, resulting in one normal 4-celled embryo which was transferred on the second day. A BHCG was positive on day 15, and a normal female infant was born at 38 weeks gestation by cesarean section. {Whether it is frozen oocytes or embryos being used, the fact remains that the child was conceived outside the loving act of the parents which is an injustice to the child. Too, the technology opens the door to permutations such that the child might have no relationship to the parents..coming out of neither the emotional and spiritual (unitive), nor the biological/genetic connection (procreative) between the parents. Ed.}
Oyesanya, O.A., et.al., Concordance of Predicted Time of Ovulation in Natural cycles with Endometrial Development Comparison Between Serial Ultrasonography and LH Assays: Implications for Protocols for the Development of Alternative Contraceptive Strategies. Fertility and Sterility, ASRM Abstracts, (Oct. 18-22, 1997).
The presenter began by stating "The knowledge of the precise timing of ovulation in relation to endometrial development in natural cycles is of paramount importance in the management of infertile women at primary, secondary and tertiary levels and for the development of strategies of fertility control." They compared ovulation predication in natural cycles using serial Ultrasound (U/S) (to determine follicular rupture), and serial LH levels (in conjunction with confirmatory endometrial biopsies) in 60 regularly cycling women of proven fertility. The concordance index was not significantly different between U/S and LH surge. At the end of the presentation, the comment was made that ultrasound was a very reliable predictor of ovulation but somewhat expensive. We know that the Peak Day as determined by natural family planning methods is as accurate as either follicular rupture or LH surge and is much less expensive than either.
Vercellini, Paolo, et.al., Menstrual Characteristics in Women With and Without Endometriosis. Obstetrics and Gynecology 90 (August 1997): 264-267.
Here the authors wanted to assess menstrual blood loss and other menstrual characteristics prospectively in women with and without endometriosis. 315 premenopausal women undergoing laparoscopy for various reasons were asked to evaluate their blood loss by the Higman blood loss assessment chart, cycle length, and flow duration. They also graded their dysmenorrhea with a 100 mm visual analog and verbal rating scale. The median pictorial blood loss score was 110 (range 66-156) in women with endometriosis (N=163) and 84 (range 56-129) in women without endometriosis (N=152). This finding was statistically significant. Menstrual flow duration was slightly longer in women with endometriosis (mean difference 0.33d). Dysmenorrhea was significantly higher in the endometriosis than the nonendometriosis group. There was, not surprisingly, a significant correlation between dysmenorrhea and blood loss assessment scores for both groups. It has long been theorized that endometriosis results from tubal regurgitation and implantation of the regurgitated endometrium. Thus a correlation between prolonged and heavy flow might be expected to be associated with endometriosis. Whether the longer heavier and more painful menses are related to endometriosis as cause or effect however could not be determined without a more objective measurement of blood loss, establishment of the relationship of transtubal to transcervical flow, and a way to determine whether exposure precedes outcome or vice-versa. Nevertheless, this is an interesting study and seems to lend some evidence in the direction of a very old theory.
Barnhardt, K.T., et.al., The Effect of DHEA replacement in the Endocrine and Lipid profiles of Perimenopausal woman. Fertility and Sterility, ASRM Abstract (Oct. 18-22, 1997).
This was an oral presentation from the 1997 ASRM Scientific Session which reported on a randomized, double blinded, placebo controlled two parallel arm trial of 30 healthy perimenopausal women ages 45-55 to investigate the impact of DHEA replacement on their endocrine and lipid profiles. Daily supplementation of 50 mg. of DHEA was used in the study group. Among others, cholesterol, HDL, LDL, Serum DHEAS, Estradiol, Testosterone, and Cortisol levels were evaluated after 1,2, and 3 months of supplementation. The results showed significant elevation in DHEAS and Testosterone levels at the 1,2, and 3 month evaluation when compared to placebo. However, these levels were not elevated above "normal". There were no statistically significant differences in the lipid levels between the study and placebo groups although there was a trend toward a decrease in Cholesterol and HDL levels in the study group. Because many women are asking about DHEAS and taking it sometimes in large quantities, it is important for those involved in women's health care as NFP providers to know what supplements are being taken and to have some idea of what the medical literature is saying with respect to these supplements. This study seems to show elevations of the androgens DHEAS and Testosterone when women took DHEA. This is of concern because of the many metabolic effects of these androgens not to mention the potential for virilizing side effects and menstrual irregularities..
NFP teachers need to be aware of the latest research regarding human sexuality, fertility/infertility, contraception, and sexually transmitted diseases. Especially with the majority of their clients coming for NFP instruction after a range of contraceptive use, it is important for the NFP teacher to be familiar with the possible effects of the various forms of contraception on the menstrual cycle. Journals treating current research on these subjects have been and continue to be, grossly expensive or hard to retrieve unless one has access to a medical or university library. With the coming of the home computer and the internet however, even the poorly funded NFP program can have access to such information and keep their teachers up to date. The following are web sites where such information can be retrieved:
Med-Line.
The United Nations publishes numbers and population information:
- For current world population figures check:www.undp.org/popin/wtrends/agespec.htm
- For the latest information on rates and trends:www.undp.org/popin/wtrends/wpgrow.htm
If you have a computer but are not on the internet, you can take advantage of two free services which the World Health Organization (WHO) offers. The first is their newsletter Progress in Human Reproduction Research, an easy to read publication which summarizes the studies reported on. The second is the WHO Reproductive Health Library (RHL), a series of computer disks which contain current medical information on reproductive health. Please note that both of these resources are tailored to developing countries in general and family planning clinicians in particular. Contact: WHO, 1211 Geneva 27, Switzerland. Please designate which (or both), resource(s) you want to receive.
News from the Billings Ovulation Method Association- USA (BOMA):
Erik Odeblad, M.D., Ph.D., of Sweden sent his latest research called Cell-to-Cell Communication. He has given BOMA first rights to publish in BOMA News and the diocese of St. Cloud's newsletter, NFP Quarterly. Although both newsletters will contain his article, BOMA News will have the information in its entirety.
Sue Ek (diocese of St. Cloud) reports that Dr. Odeblad noted the text presents the ideas of cell-to-cell communication.
BOMA News is available for members only - an annual membership is $25.00, per individual or $50.00 per organization. Besides receiving the newsletter, members receive quarterly issues of the Drs. Billings newsletter from Australia -"Bulletin of the Ovulation Method Research and Reference Centre of Austrlia." Members also receive an annual directory of Billings instructors in the U.S. Contact: BOMA-USA, 316 North 7th Ave., St. Cloud, MN 56303-3631; 320-252-2100 or 1-888-637-6371; FAX: 320-252-2877; E-mail: nfpstc@cloudnet.com